Literature DB >> 34129058

The molecular basis and cellular effects of distinct CD103 expression on CD4 and CD8 T cells.

Davinna L Ligons1, Can Li1, Hilary R Keller1,2, SuJin Hwang1, Megan A Luckey1, Praveen Prakhar1, Nurcin Liman1, Assiatu Crossman1, Vanja Lazarevic1, Yoo Kyoung Park3, Jung-Hyun Park4.   

Abstract

Integrin CD103 mediates the adhesion and tissue retention of T cells by binding to E-cadherin which is abundant on epithelial cells. Notably, CD103 is highly expressed on CD8 T cells but conspicuously absent on most CD4 T cells. The mechanism controlling such lineage-specific expression of CD103 remains unclear. Using a series of genetically engineered mouse models, here, we demonstrate that the regulatory mechanism of CD103 expression is distinct between CD4 and CD8 T cells, and that the transcription factor Runx3 plays an important but not an essential role in this process. We further found that the availability of integrin β7 which heterodimerizes with CD103 was necessary but also constrained the surface expression of CD103. Notably, the forced surface expression of CD103 did not significantly alter the thymic development of conventional T cells but severely impaired the generation of MHC-II-restricted TCR transgenic T cells, revealing previously unappreciated aspects of CD103 in the selection and maturation of CD4 T cells. Unlike its effect on CD4 T cell development, however, CD103 overexpression did not significantly affect CD4 T cells in peripheral tissues. Moreover, the frequency and number of CD4 T cells in the small intestine epithelium did not increase even though E-cadherin is highly expressed in this tissue. Collectively, these results suggest that most mature CD4 T cells are refractory to the effects of CD103 expression, and that they presumably utilize CD103-independent pathways to control their tissue retention and residency.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  CD103; Integrin; Intraepithelial lymphocytes; Runx3; TGFβ

Mesh:

Substances:

Year:  2021        PMID: 34129058      PMCID: PMC9293543          DOI: 10.1007/s00018-021-03877-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.207


  43 in total

1.  Expression of CD103 identifies human regulatory T-cell subsets.

Authors:  Zoulfia Allakhverdi; David Fitzpatrick; Annie Boisvert; Nobuyasu Baba; Salim Bouguermouh; Marika Sarfati; Guy Delespesse
Journal:  J Allergy Clin Immunol       Date:  2006-09-18       Impact factor: 10.793

2.  CD8+ recent thymic emigrants home to and efficiently repopulate the small intestine epithelium.

Authors:  Tracy L Staton; Aida Habtezion; Monte M Winslow; Tohru Sato; Paul E Love; Eugene C Butcher
Journal:  Nat Immunol       Date:  2006-04-02       Impact factor: 25.606

3.  E-cadherin-mediated interactions of thymic epithelial cells with CD103+ thymocytes lead to enhanced thymocyte cell proliferation.

Authors:  Snjezana Kutlesa; Johannes T Wessels; Angelika Speiser; Inge Steiert; Claudia A Müller; Gerd Klein
Journal:  J Cell Sci       Date:  2002-12-01       Impact factor: 5.285

4.  A role for CCR9 in T lymphocyte development and migration.

Authors:  Shoji Uehara; Alexander Grinberg; Joshua M Farber; Paul E Love
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

5.  Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice.

Authors:  M P Schön; A Arya; E A Murphy; C M Adams; U G Strauch; W W Agace; J Marsal; J P Donohue; H Her; D R Beier; S Olson; L Lefrancois; M B Brenner; M J Grusby; C M Parker
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

6.  Runx3 regulates integrin alpha E/CD103 and CD4 expression during development of CD4-/CD8+ T cells.

Authors:  Baerbel Grueter; Michaela Petter; Takeshi Egawa; Kirsten Laule-Kilian; Christine J Aldrian; Andreas Wuerch; Yvonne Ludwig; Hidehiro Fukuyama; Hedda Wardemann; Ralph Waldschuetz; Tarik Möröy; Ichiro Taniuchi; Viktor Steimle; Dan R Littman; Marc Ehlers
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

7.  CD69 cell surface expression identifies developing thymocytes which audition for T cell antigen receptor-mediated positive selection.

Authors:  I Yamashita; T Nagata; T Tada; T Nakayama
Journal:  Int Immunol       Date:  1993-09       Impact factor: 4.823

Review 8.  CD4CD8αα IELs: They Have Something to Say.

Authors:  Chao Zhou; Yuan Qiu; Hua Yang
Journal:  Front Immunol       Date:  2019-10-09       Impact factor: 7.561

9.  Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs.

Authors:  Fernando Cruz-Guilloty; Matthew E Pipkin; Ivana M Djuretic; Ditsa Levanon; Joseph Lotem; Mathias G Lichtenheld; Yoram Groner; Anjana Rao
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

10.  In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death.

Authors:  M L Hermiston; J I Gordon
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  2 in total

1.  Chemokine receptor CCR9 suppresses the differentiation of CD4+CD8αα+ intraepithelial T cells in the gut.

Authors:  Can Li; Hye Kyung Kim; Praveen Prakhar; Shunqun Luo; Assiatu Crossman; Davinna L Ligons; Megan A Luckey; Parirokh Awasthi; Ronald E Gress; Jung-Hyun Park
Journal:  Mucosal Immunol       Date:  2022-07-01       Impact factor: 8.701

2.  Runx3 drives a CD8+ T cell tissue residency program that is absent in CD4+ T cells.

Authors:  Raíssa Fonseca; Thomas N Burn; Luke C Gandolfo; Sapna Devi; Simone L Park; Andreas Obers; Maximilien Evrard; Susan N Christo; Frank A Buquicchio; Caleb A Lareau; Keely M McDonald; Sarah K Sandford; Natasha M Zamudio; Nagela G Zanluqui; Ali Zaid; Terence P Speed; Ansuman T Satpathy; Scott N Mueller; Francis R Carbone; Laura K Mackay
Journal:  Nat Immunol       Date:  2022-07-26       Impact factor: 31.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.